Article info
Original research
Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
- Correspondence to Dr Robert D Morgan, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK; robert.morgan7{at}nhs.net
Citation
Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Publication history
- Received May 2, 2022
- Accepted June 9, 2022
- First published June 23, 2022.
Online issue publication
October 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.